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Abstract 
 
Diet-induced muscle insulin resistance is associated with expansion of extracellular matrix 
(ECM) components such as collagens and the expression of collagen binding integrin, α2β1. 
Integrins transduce signals from ECM via their cytoplasmic domains, which bind to intracellular 
integrin binding proteins.  The ILK-PINCH-parvin (IPP) complex interacts with the cytoplasmic 
domain of β integrin subunits and is critical for integrin signaling.  In this study we defined the 
role of integrin-linked kinase (ILK), a key component of the IPP, in diet-induced muscle insulin 
resistance.  Wildtype (ILKlox/lox) and muscle-specific ILK-deficient (ILKlox/loxHSAcre) mice were 
chow fed or high fat (HF) fed for 16wks. Body weight was not different between ILKlox/lox and 
ILKlox/loxHSAcre mice.  However, HF-fed ILKlox/loxHSAcre mice had improved muscle insulin 
sensitivity relative to HF-fed ILKlox/lox mice as shown by increased rates of glucose infusion, 
glucose disappearance, and muscle glucose uptake during a hyperinsulinemic-euglycemic clamp. 
Improved muscle insulin action in the HF-fed ILKlox/loxHSAcre mice was associated with 
increased insulin-stimulated phosphorylation of Akt and increased muscle capillarization.  These 
results suggest that ILK expression in muscle is a critical component of diet-induced insulin 
resistance, which possibly acts by impairing insulin signaling and insulin perfusion through 
capillaries. 
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Introduction 
 
Insulin resistance is a commonly associated risk factor for many pathophysiological 
conditions including diabetes, cardiovascular diseases, neurological changes, liver diseases, and 
sleep apnea (1,2).  A defect in glucose utilization in the skeletal muscle is a major component of 
insulin resistance.  The pathogenesis of muscle insulin resistance is not fully understood and 
pharmacological interventions that reduce insulin resistance are limited and often lose efficacy 
over time (e.g. biguanides) or have adverse side effects (e.g. thiazolidinediones) (3). Our recent 
studies have suggested a novel role for extramyocellular factors in regulating muscle insulin 
action. Expansion of extracellular matrix (ECM) components such as the collagens and the 
expression of the collagen binding integrin α2β1 are associated with high fat (HF) diet-induced 
muscle insulin resistance (4).  The ECM is in direct contact with the muscle capillaries.  Defects 
in recruitment of muscle capillaries contribute to the development of muscle insulin resistance 
(5). Transduction of ECM signals through integrins requires interaction of the integrin 
cytoplasmic domains with cellular proteins. To investigate the link between ECM-integrin 
signaling and muscle insulin resistance, we studied a highly-conserved central downstream 
component of the ECM-integrin signaling, integrin-linked kinase (ILK) and its role in muscle 
insulin resistance. 
ILK is a pseudo-kinase with adaptor function.  It is a central component of the ILK- 
PINCH-parvin complex (IPP) (6).  This complex binds to the cytoplasmic domain of β integrin 
subunits.  The IPP complex functions as an adaptor between integrins and the actin cytoskeleton, 
therefore regulating multiple cellular functions including cell spreading, migration, proliferation, 
survival, and cell-cell adhesion (7,8).  IPP also acts as a hub of the downstream of integrin 
signaling that regulates several other signaling pathways. The IPP complex associates with the 
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receptor tyrosine kinase (RTK) pathways (e.g. insulin receptor pathway) through protein NCK2, 
which binds to PINCH (9).  Considering the important role of RTK signaling in metabolism, we 
propose that ILK is fundamental to metabolic regulation.  In the current study, we tested the 
hypothesis that the expansion of ECM collagen will amplify activation of integrin receptor 
signaling through ILK and regulate insulin signaling, thereby contributing to muscle insulin 
resistance.  Muscle-specific ILK knockout mice were utilized to investigate the contribution of 
ILK signaling in chow-fed and HF-fed mice, a well-established model of insulin resistance (10). 
Our results reveal that integrin receptor signaling through ILK is critical to the pathogenesis of 
insulin resistance. 
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Research Design and Methods 
Mouse Models 
All mice were housed in cages under conditions of controlled temperature and humidity 
with a 12-h light/dark cycle. Transgenic mice expressing Cre under a human alpha-skeletal actin 
(HSA or ACTA1) promoter (Jackson Laboratory Stock# 006149) were crossed with floxed ILK 
mice (ILKlox/lox) (11,12), to obtain the muscle-specific ILK deficient mice (ILKlox/loxHSAcre).  
All mice were on a C57BL/6J background and were fed either a chow (LabDiet #5001), or HF 
diet (BioServ F3282) starting at 3 weeks of age (at weaning), for 16 weeks unless stated 
otherwise.  All mice had ad libitum access to food and water.  The calorie breakdown was 29% 
protein, 13% fat, and 58% carbohydrate for the chow diet, and 15% protein, 59% fat, and 26% 
carbohydrate for the HF diet.  Noticeably, the HF diet is also a low protein, low carbohydrate 
diet compared to the chow diet.  Male mice were used in the study because of their more robust 
insulin-resistant phenotype after HF feeding as compared to female mice.  In addition, female 
mice introduce a number of biological variables for which there is currently limited data and as 
such it is difficult to adequately interpret results. Body composition was determined by a mq10 
nuclear magnetic resonance analyzer (Brucker optics). The Vanderbilt and Dundee Animal Care 
and Use Committee approved all animal procedures. 
 
 
 
Hyperinsulinemic-Euglycemic Clamp (ICv) 
 
Catheters were implanted in a carotid artery and a jugular vein of mice for sampling and 
intravenous infusions 5 days before ICv (13).  ICv (4mU/kg/min) was performed on 5hr-fasted 
mice since they have ample glycogen stores and do not undergo the dramatic weight loss seen 
after an overnight fast (13).  [3-3H]glucose was infused to determine glucose flux rates (14). 
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Blood glucose was clamped at ~150mg/dL using a variable glucose infusion (GIR). Mice 
received washed erythrocytes from donors to prevent the drop in hematocrit that would 
otherwise occur.  ICv was achieved by assessment of blood glucose every 10min with GIR 
adjusted as needed.  Blood was taken at 80-120min for the determination of [3-3H]glucose. 
Clamp insulin was determined at t=100 and 120min.  At 120min the clamp was sustained and a 
13µCi 2[14C]deoxyglucose ([14C]2DG) bolus was administered. Blood was taken at 122-155min 
for [14C]2DG determination.  After the last sample, mice were anesthetized and tissues were 
excised. 
 
 
 
ICv Plasma and Tissue Sample Processing and Glucose Flux Rate Determination 
 
Plasma insulin was determined using the insulin ELISA kit (Millipore). Non-esterified 
fatty acid (NEFA) concentrations were measured by an enzymatic colorimetric assay (NEFA C 
kit, Wako Chemicals).  Liver triglyceride was measured using the GPO triglyceride kit (Pointe 
Scientific, Cat#T7532) in ~100mg frozen liver.  Plasma and tissue radioactivity of [3-3H]glucose, 
[14C]2DG, and [14C]2DG-6-phosphate were determined as described (15).  Glucose appearance 
(Ra), endogenous glucose appearance (EndoRa), and glucose disappearance (Rd) rates were 
determined using non-steady-state equations (16).  The glucose metabolic index (Rg) was 
calculated as described (17). 
 
 
 
Immunohistochemistry 
 
ILK, collagen IV (ColIV), laminin, CD31, and Von Willebrand Factor (vWF) were 
assessed by immunohistochemistry in paraffin-embedded gastrocnemius tissue sections (5μm) 
using the following primary antibodies: anti-ILK (1:150, Santa Cruz, sc-20019), anti-ColIV 
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(1:100; Abcam, ab6586), anti-laminin (1:3000, DakoCytomation, Z0097), anti-CD31 (1:200, BD 
Biosciences, 550274), and anti-vWF (1:3000, DakoCytomation, A0082). Slides were lightly 
counterstained with Mayer’s hematoxylin.  The EnVision+HRP/DAB System (DakoCytomation) 
was used to produce localized, visible staining.  Images were captured using a Q-Imaging 
Micropublisher camera mounted on an Olympus upright microscope.  Immunostaining was 
quantified by ImageJ or BIOQUANT Life Science 2009.  ILK, ColIV, and laminin protein was 
measured by the integrated intensity of staining.  Muscle vascularity was determined by counting 
CD31 positive structures and by measuring areas of vWF positive structures. Average fiber 
diameter of gastrocnemius muscle was manually measured from laminin staining images. At 
least 15 fibers were measured per image and 6 images were measured per animal. 
 
 
 
Immunoprecipitation and Immunoblotting 
 
Gastrocnemius was homogenized as described (4).  Protein (40μg) was applied to SDS- 
PAGE gel.  The following antibodies were used to detect respective proteins: ILK (1:1000, Santa 
Cruz, sc-20019), insulin receptor substrate 1 (IRS-1) (1:1000, Cell Signaling, #2382), phospho- 
Akt (Ser473) (1:1000, Cell Signaling, #9271), total Akt (1:1000, Cell Signaling, #9272), 
phospho-P38 (1:1000, Cell Signaling, #9211), total P38 (1:1000, Cell Signaling, #9212), 
 
phospho-ERK1/2 (1:2000, Cell Signaling, #4370), total ERK1/2 (1:1000, Cell Signaling, #4695), 
 
phospho-JNK (1:1000, Cell Signaling, #9251) and total JNK (1:1000, Cell Signaling, #9252), 
and p-Tyr (PY99) (1:1500, Santa Cruz, sc-7020).  GAPDH (1:2000, Cell Signaling, #5174) was 
used as a loading control.  For immunoprecipitation, 500µg of protein was pre-cleared with 50μL 
of protein A/G PLUS-Agarose beads by incubation at 4°C for 1 hour. Protein supernatant was 
then incubated with the insulin receptor β (IRβ) antibody (1:50, Cell Signaling, #3025) at 4°C for 
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overnight.  Then, 20µL protein A/G PLUS-Agarose was added and incubated. The mixture was 
centrifuged and the supernatant removed. The beads were washed four times and centrifugation 
was repeated.  Beads were re-suspended and applied to SDS-PAGE gel.  Immunoblots were 
probed with primary antibodies for p-Tyr (PY99) (1:1500, Santa Cruz, sc-7020) and IRβ (4B8) 
(1:1000, Cell Signaling, #3025). 
 
 
 
Food Intake and Wet Gastrocnemius Weight 
 
Food intake and gastrocnemius muscle weight were measured in HF-fed mice after 27 
weeks of HF feeding.  Average food intake for light and dark cycle was measured by Promethion 
System (Sable Systems International). Wet gastrocnemius muscle was collected and weighed 
from 5h-fasted mice. 
 
 
 
Statistical Analysis 
 
Data are expressed as mean ± SEM. Statistical analyses were performed using either 
student’s t test or two-way ANOVA followed by Tukey’s post hoc tests as appropriate. The 
significance level was at p<0.05. 
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Results 
 
To elucidate the role of ILK in muscle insulin resistance, muscle-specific ILK deficient 
mice (ILKlox/loxHSAcre) and their wild type littermate controls (ILKlox/lox) were fed a chow or a 
HF diet, which has been previously defined to induce muscle insulin resistance (10). 
Immunohistochemical staining of ILK revealed that ILK was exclusively deleted from the 
muscle fibers of ILKlox/loxHSAcre mice, but remained in the other cell types, such as endothelial 
cells (Figure 1A).  HF diet feeding alone did not affect ILK expression in the muscle (Figure 1B). 
Deletion of ILK in skeletal muscle fibers did not affect weight gain of mice on either diet (Figure 
2A). The percent fat and lean masses did not differ between ILKlox/lox and ILKlox/loxHSAcre mice 
regardless of diet (Figures 2B and 2C).  Consistent with unchanged percent lean mass, wet 
gastrocnemius muscle weight was not different between HF-fed ILKlox/lox and ILKlox/loxHSAcre 
mice (Figure 2D).  Food intake was the same between the two groups of mice on HF diet (Figure 
2E). 
To investigate the metabolic consequences of muscle-specific deletion of ILK, mice 
underwent ICv clamps. Basal arterial glucose (t=0min) was not different between chow-fed 
ILKlox/lox and ILKlox/loxHSAcre mice, but was significantly decreased in the HF-fed 
ILKlox/loxHSAcre mice (Figures 3A and 3B).  ICv glucose during the steady state of the clamp 
(t=80-120min) was 150mg/dL in both genotypes and in mice on both diets (Figures 3A and 3B). 
In chow-fed mice, ICv GIR was the same between ILKlox/lox and ILKlox/loxHSAcre mice, 
indicating no difference in insulin sensitivity (Figure 3C). Basal EndoRa and Rd were the same 
between chow-fed ILKlox/lox and ILKlox/loxHSAcre mice (Figure 3E). EndoRa was equivalently 
suppressed and Rd was equivalently increased during the ICv in both genotypes (Figure 3E).  In 
contrast, ICv GIR was markedly increased in the HF-fed ILKlox/loxHSAcre mice compared to HF- 
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fed ILKlox/lox mice, indicating an improved response to insulin (Figure 3D).  This increase in GIR 
in ILKlox/loxHSAcre was due to an increase in clamp Rd (Figure 3F). The inhibition of EndoRa 
during the ICv was unaffected by genotypes, emphasizing the muscle-specific effect on insulin 
action (Figure 3F).  Increased clamp Rd in HF-fed ILKlox/loxHSAcre mice was attributed to both 
increased glycolytic and glucose storage rates, which were estimated by the rate of plasma 3H- 
H2O accumulation during the ICv clamp (Figure S1). 
Rg in muscles was decreased in HF-fed ILKlox/lox mice compared to chow-fed ILKlox/lox 
mice, indicative of HF diet-induced insulin resistance (Figure 4A). Muscle Rg was unaffected 
by ILK deletion in chow-fed mice.  Remarkably, the HF-induced muscle Rg impairment was 
absent in the HF-fed ILKlox/loxHSAcre mice (Figure 4A). Rg in adipose tissue was not different 
between ILKlox/lox and ILKlox/loxHSAcre mice regardless of diet (Figure 4A). Taken together, 
these data suggest that muscle-specific deletion of ILK in mice improved HF diet-induced 
insulin resistance specifically in muscle.  This improvement of insulin resistance is independent 
of adiposity. 
Basal plasma NEFA concentrations were not affected by genotype or diet (Figure 4B). 
Despite the same plasma NEFA concentrations between chow-fed ILKlox/lox and 
ILKlox/loxHSAcre mice during the ICv, ICv plasma NEFA was significantly lower in the HF-fed 
ILKlox/loxHSAcre mice compared to HF-fed ILKlox/lox mice, indicative of an improved ability of 
insulin to inhibit lipolysis (Figure 4B). While basal arterial insulin was not affected by ILK 
deletion in the chow-fed mice, muscle-specific ILK deletion significantly lowered basal arterial 
insulin in the HF-fed mice, suggesting improved insulin sensitivity (Figure 4C).  It is worth 
noting that basal arterial insulin concentration in HF-fed ILKlox/loxHSAcre mice was still 
substantially higher than that in chow-fed mice. These data together with a defect seen in 
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glycogen storage in HF-fed ILKlox/loxHSAcre mice compared to that in chow-fed mice (Figure S1) 
suggest that HF-fed ILKlox/loxHSAcre mice were still insulin resistant despite the marked 
improvement in muscle Rg.  Insulin concentrations during the ICv were equivalent between 
genotypes (Figure 4C).  Even though insulin action in the liver as assessed by EndoRa was 
unaffected (Figure 3F), liver triglyceride content was significantly decreased in the HF-fed 
ILKlox/loxHSAcre mice compared to HF-fed ILKlox/lox mice (Figure 4D).  This suggests that the 
muscle metabolic status can convey a signal to liver that reduces triglyceride accumulation. 
Similarly, we also found changes in the status of adipose inflammation (Figure S2). Gene 
expression of total macrophage marker F4/80 was increased in ILKlox/loxHSAcre mice compared 
to ILKlox/lox mice regardless of diet (Figure S2A).  Gene expression of the pro-inflammatory 
marker TNFα was increased in ILKlox/lox mice by HF feeding, but interestingly this diet effect 
was absent in ILKlox/loxHSAcre mice (Figure S2B).  In contrast, gene expression of the anti- 
 
inflammatory markers IL-10 and Arg-1 was increased in HF-fed ILKlox/loxHSAcre mice 
compared to HF-fed ILKlox/lox mice (Figure S2C).  These effects of muscle ILK deletion on liver 
and adipose tissue were associated with an increase in IL-6 mRNA levels in muscle of HF-fed 
ILKlox/loxHSAcre mice compared to HF-fed ILKlox/lox mice (Figure S2D). 
We further investigated the mechanisms by which HF-fed ILKlox/loxHSAcre mice had 
 
improved muscle insulin resistance.  Elevated ECM deposition has been associated with HF diet- 
induced muscle insulin resistance (4,18,19). We examined the ECM collagen and laminin 
content in the muscle.  Consistent with previous findings (4), muscle collagen IV deposition was 
increased by 2-fold with HF feeding in ILKlox/lox mice, while muscle laminin deposition was not 
affected (Figures 5A and 5B). Neither collagen IV nor laminin was affected by ILK deletion. 
Moreover, the average fiber diameter of gastrocnemius muscle was not changed by genotype or 
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HF diet (Figure 5C).  Interestingly, improved muscle insulin resistance in HF-fed 
ILKlox/loxHSAcre mice was associated with increased CD31 staining in muscle of HF-fed 
ILKlox/loxHSAcre mice compared to HF-fed ILKlox/lox mice, indicating increased CD31-positive 
capillarization (Figures 5D and 5E). There was no change in vWF staining indicating that larger 
vessels were unaffected (Figures 5D and 5E). 
We next investigated insulin signaling in the muscle. While improved muscle insulin 
resistance in HF-fed ILKlox/loxHSAcre mice was not associated with increased phosphorylation of 
insulin receptor (Figures 6A and 6B) or insulin receptor substrate-1 (IRS-1) (Figures 6C and 6D), 
improved muscle insulin action was associated with increased phosphorylated and total Akt/PKB 
(Figures 6C and 6E).  This effect is specific to insulin-stimulated conditions as phosphorylated 
and total Akt/PKB was not increased in the basal 5h-fasted muscles (Figures 6F and 6G). 
Mitogen-activated protein kinases (MAPKs) have been shown to negatively regulate 
endothelial cell survival, proliferation, and differentiation (20). We investigated whether the 
increased muscle capillarization in the HF-fed ILKlox/loxHSAcre mice were associated with 
altered MAPKs pathway.  While HF diet feeding caused an increase in ratios of p-P38/P38 and 
p-JNK/JNK, this diet effect was absent in the HF-fed ILKlox/loxHSAcre mice (Figures 7A-D). 
Moreover, p-ERK/ERK ratio was decreased in the HF-fed ILKlox/loxHSAcre compared to HF-fed 
ILKlox/lox mice (Figures 7E and 7F).  These results are consistent with the prior assertion that 
capillarization may be upregulated by a decrease in MAPK activation (20). 
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Discussion 
 
ECM expansion and the interaction of protein constituents with the cell surface receptor 
integrin α2β1 have been found recently to contribute to the pathogenesis of HF diet-induced 
muscle insulin resistance (4,18,19).  There appear to be α subunit specific effects of integrin- 
ligand binding (21), as integrin α1β1 does not appear to contribute to diet-induced muscle insulin 
resistance (4,22). The ILK pseudokinase, is a central component of the IPP complex which 
binds to the cytoplasmic domains of both integrin α1β1 and α2β1, and therefore its expression 
may be a better reflection of the integrated integrin response.  Here we show that while muscle- 
specific deletion of ILK has no effect in lean, chow-fed mice it, improves HF diet-induced 
muscle insulin resistance.  The improvement in insulin-stimulated glucose fluxes is specific to 
muscle as the ability of insulin to inhibit hepatic glucose production and to stimulate glucose 
uptake in adipose tissue are not affected. We further discovered that improved muscle insulin 
resistance in the ILK-deficient mice is associated with increased phosphorylation of Akt and 
increased muscle capillarization.  These findings show that ILK is central to insulin resistance 
associated with HF feeding.  An extension of these findings is that ILK inhibition is of potential 
therapeutic use in the treatment of diabetes and other insulin resistance-associated metabolic 
disorders. 
We establish a working model in the current study by which insulin signaling and  
integrin signaling interact at the level of Akt (Figure 8). Although ILK is a pseudokinase, it 
contains a catalytically inactive remnant of an active kinase that uses its substrate recognition 
motif to interact with other proteins that have well-conserved motifs required for eukaryotic 
protein kinase activity (23).  Our results show that muscle-specific deletion of ILK increases 
phosphorylation of Akt at Ser 473 in HF-fed mice and this effect is specific to insulin stimulation 
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as basal Akt phosphorylation was not affected in these mice.  While the precise steps how ILK 
regulates phosphorylation of Akt during the stimulation of insulin are uncertain, studies of ILK 
in cell adhesion and survival provide a basis for linkage. Rictor directly interacts with ILK and 
regulates Akt phosphorylation promoting cancer cell survival (24). Moreover, it is widely 
proposed that ILK associates with the receptor tyrosine kinase (RTK) pathways (e.g. insulin 
receptor pathway) through protein NCK2, which binds to PINCH, one of the components of the 
IPP complex (9).  The other possibility is that ILK controls Akt activity by regulating its 
subcellular localization as ILK-binding partners, α- and β-parvins induce the recruitment of Akt 
to the plasma membrane (25,26).  It is noteworthy that the majority of studies in ILK has focused 
on signaling involved in cell spreading, adhesion, migration and survival, therefore the ILK- 
mediated signaling in metabolic regulation could be significantly different. 
Reduction in blood flow to the muscle correlates with insulin resistance and the number 
of capillaries that perfuse the muscle is positively related to peripheral insulin action (27).  In the 
current study, we found that improvement of muscle insulin resistance in HF-fed obese mice by 
muscle-specific ILK deletion is associated with increased expression of vascular/endothelial 
marker, CD31 in muscle.  This finding is consistent with a previous study that shows that genetic 
integrin α2β1 deletion-improved muscle insulin resistance is associated with increased muscle 
capillaries (4).  In contrast, exacerbated insulin resistance in HF-fed matrix metalloproteinase 9 
(MMP9)-deficient mice, where muscle collagen deposition is increased, is associated with 
decreased muscle capillaries (19).  Activation of MAPK pathways negatively regulate 
endothelial cell survival, proliferation, and differentiation (20). We found that increased muscle 
capillarization in the HF-fed ILK deficient mice are associated with decreased phosphorylation 
of several MAPKs including P38, ERK1/2, and JNK. The regulation of ILK in the MAPK 
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pathways is thought to be through Ras suppression protein 1 (RSU1), which binds to ILK via 
Pinch-1 (28). Taken together, these results indicate that ILK expression in muscle may stimulate 
activation of various MAPKs pathways, which in turn inhibit capillary proliferation and 
endothelial function (Figure 8).  Both inhibited phosphorylation of Akt and inhibited capillary 
proliferation induced by muscle ILK expression during insulin stimulation are likely mechanisms 
that contribute to the development of insulin resistance in the presence of HF diet (Figure 8). 
The effect of muscle-specific deletion of ILK on overall total blood flow in muscle is 
unknown.  It is unlikely that ILK deletion has a major impact on muscle blood flow as the 
expression of vWF, a vascular marker for bigger vessels was not changed in the ILK deficient 
mice (Figures 5D and 5E). However, the increase in CD31 suggests that capillarization is 
increased. We hypothesize that improved muscle capillarization leads to greater exchange of 
insulin and other hormones from blood to muscle.  Improved insulin access to muscle could 
contribute to improved insulin action in the HF-fed ILK deficient mice. 
It is worth noting that considerable evidence in the literature suggests that HF diet- 
induced insulin resistance in skeletal muscle is associated with a remodeling of actin 
cytoskeleton (29).  ILK, as a central component of the IPP complex which links integrins to actin 
cytoskeleton is essential for actin cytoskeleton organization and morphology (30).  It is possible 
that deletion of ILK in muscle improves HF diet-induced insulin resistance through effects on 
reorganization of actin cytoskeleton.  Moreover, it is possible that deletion of ILK in muscle may 
cause an alteration in muscle fiber type during HF feeding. This seems unlikely since Gheyara et 
al. has previously shown that ILK deletion does not change muscle fiber type proportions or 
distribution in the quadriceps of chow-fed mice (31).  Nevertheless, we cannot rule out that a 
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switch in muscle fiber type to a more oxidative profile could occur during HF feeding and 
contribute to improved muscle insulin resistance in mice lacking muscle ILK. 
It has been previously shown that muscle-specific deletion of ILK causes a progressive 
muscular dystrophy (31).  This phenomenon is associated with disrupted focal adhesion proteins, 
including vinculin, paxillin, focal adhesion kinase, dystrophin, and the integrin α7β1 specifically 
at the myofascial junction regions. Gheyara et al. reported that the muscle damage was limited 
to the myofascial junction regions in young ILK mutant mice (31). Our current study focused at 
the muscle fiber level and was able to show that ILK was specifically deleted from the muscle 
fibers using immunohistochemistry.  We showed that muscle collagens and laminin expression 
were not affected by ILK deletion.  Importantly, we showed that total body weight and the %fat 
and %lean mass of both chow-fed and HF-fed mice were unchanged by ILK deletion. These 
results suggest that while ILK deletion may have aging-related structure and focal adhesion 
phenotypes in the myofascial junction areas, it retains a robust insulin-stimulatory response. 
The development of pharmacological inhibition of ILK by small-molecule inhibitors has 
primarily focused on inhibiting its kinase activity (32,33). Because ILK is a scaffold protein 
rather than a kinase, none of these inhibitors are specific to ILK.  Therefore, we believe that the 
development of pharmacological inhibition of ILK that targets its binding motifs is under high 
demand in future studies.  Our studies show that ILK deletion has a remarkable impact on 
improving insulin sensitivity. Thus, these studies further implicate the importance of inhibition 
of ILK in the setting of diabetes and associated metabolic disorders. 
In conclusion, our results suggest that muscle-specific deletion of ILK markedly 
improves muscle insulin sensitivity in HF-fed insulin resistant mice via increased 
phosphorylation of Akt in addition to increased muscle capillarization. The increased 
17  
capillarization is associated with decreased phosphorylation of MAPKs. These studies are the 
first linking ECM-integrin signaling to muscle insulin resistance via ILK and provide a 
mechanistic framework for the importance of ECM-integrin-ILK in metabolic regulation. The 
results open the door to the development of inhibitors of ILK signaling in the treatment of insulin 
resistance and its related metabolic disorders. 
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Figure Legends 
 
Figure 1.  Protein expression of ILK in muscle.  (A) Immunohistochemical staining of ILK in 
paraffin-embedded gastrocnemius sections from chow-fed mice (n=5). The magnification of 
images was 20X.  Representative images are presented. Arrow heads indicate intact ILK 
expression in non-myocytes.  (B) Western Blotting of ILK in whole gastrocnemius muscle 
lysates from chow-fed and HF-fed ILKlox/lox mice (n=3-4).  All data are represented as mean ± 
SEM.  Data are normalized to Chow ILKlox/lox.  HF, high fat. 
 
 
 
Figure 2.  Body weight, body composition, gastrocnemius weight, and food intake of the 
muscle-specific ILK deficient mice.  (A) Body weights of chow-fed and HF-fed ILKlox/lox and 
ILKlox/loxHSAcre mice up to 14 weeks of diet starting at 3 weeks of age (n=4-12). (B-C) Percent 
fat and lean masses were determined in mice after 14 weeks of diet (n=4-12).  (D) 
Gastrocnemius muscle was collected and weighed in 5hr-fasted mice after 27 weeks of HF diet 
(n=5). (E) Food intake during the light and dark cycle was measured in mice after 27 weeks of 
HF diet (n=4).  All data are represented as mean ± SEM. HF, high fat. 
 
 
 
Figure 3.  Insulin action as assessed by the hyperinsulinemic-euglycemic clamp (ICv). Mice 
underwent ICv experiments after 16 weeks of HF or chow diet feeding at 19 weeks of age.  (A-B) 
Blood glucose during the ICv (n=5-9).  (C-D) Glucose infusion rate during the ICv (n=5-9). (E- 
F) Endogenous glucose appearance (EndoRa) and glucose disappearance (Rd) rates were 
determined by [3-3H]glucose (n=5-9). All data are represented as mean ± SEM.  *p<0.05 HF-fed 
ILKlox/lox vs. HF-fed ILKlox/loxHSAcre.  #p<0.05 Basal vs. Clamp with the same genotype. §, 
p<0.05 for the main genotype effect.  HF, high fat. 
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Figure 4.  Muscle glucose uptake, circulating insulin, plasma non-esterified fatty acid 
(NEFA), and liver triglyceride.  (A) Rg, an index of glucose metabolic rate was determined by 
2-[14C]deoxyglucose (n=5-9).  (B) Plasma NEFA was determined at basal (-15 and -5min) and 
during the steady state of the ICv (80 and 120min) (n=5-9).  (C) Plasma insulin concentration 
was measured at basal (-15 and -5min) and during the steady state of the ICv (100 and 120min) 
(n=5-9).  (D) Liver triglyceride was determined in liver samples collected at the end of the ICv 
(n=5-9).  All data are represented as mean ± SEM.  #p<0.05 Chow vs. HF with the same 
genotype.  *p<0.05.  HF, high fat.  SVL, superficial vastus lateralis. 
 
 
 
Figure 5.  Muscle ECM deposition, fiber diameter and vascular markers of the muscle- 
specific ILK deficient mice. (A) Immunohistochemical detection of collagen IV and laminin in 
paraffin-embedded gastrocnemius sections (n=5-9). The magnification of images was 20X. 
Representative images are presented.  (B) Values represent mean ± SEM of integrated intensity 
of staining for collagen IV and laminin. Data are normalized to Chow ILKlox/lox.  (C) Average 
fiber diameter was manually measured from laminin staining images (n=5-9).  (D) 
Immunohistochemical staining of CD31 and vWF in paraffin-embedded gastrocnemius sections 
(n=5-9).  The magnification of images was 20X.  Representative images are presented. (E) 
Values represent mean ± SEM of numbers of CD31 positive structures, or of areas occupied by 
vWF positive structures.  Data are normalized to Chow ILKlox/lox. * and # indicate p<0.05.  HF, 
high fat.  vWF, Von Willebrand Factor. 
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Figure 6.  Insulin signaling in the muscle. Muscle homogenates were prepared from 
gastrocnemius collected from mice post the hyperinsulinemic-euglycemic clamp (A-E) or from 
mice after a basal 5h fast (F-G).  (A) IRβ was immunoprecipitated followed by immunoblotting 
of pY99 and IRβ.  Representative bands are presented (n=4-6).  (B) Quantitative data for Panel 
(A).  (C) Phosphorylation of IRS-1 was determined by immunoblotting of pY99 at 180kDa. 
Total IRS-1, p-Akt, and total Akt was measured by Western blotting. Representative bands are 
presented (n=4-6).  (D) Quantitative date for the Western blotting of PY99 at 180kDa and total 
IRS-1 from Panel (C). (E) Quantitative data for the Western blotting of phosphorylated Akt and 
total Akt from Panel (C).  Data are normalized to Chow ILKlox/lox.  (F) Western blotting of 
phosphorylated Akt and total Akt in basal 5h-fasted gastrocnemius tissues (n=4).  (G) 
Quantitative data for Panel (F).  All data are represented as mean ± SEM.  #p<0.05 Chow vs. HF 
with the same genotype.  *p<0.05.  HF, high fat. IRβ, insulin receptor β. IRS-1, insulin receptor 
substrate 1. pY, phospho-tyrosine. 
 
 
 
Figure 7.  P38, JNK, and ERK mitogen-activated protein kinases in the muscle.  Western 
blotting of phosphorylated P38 and total P38 (A), phosphorylated JNK and total JNK (C), and 
phosphorylated ERK and total ERK (E) in gastrocnemius homogenates isolated from mice post 
the hyperinsulinemic-euglycemic clamp. Representative bands are presented (n=4-6). (B, D, 
and F) Quantitative data for the Western blotting.  All data are represented as mean ± SEM. 
Data are normalized to Chow ILKlox/lox.  #p<0.05 Chow vs. HF with the same genotype.  *p<0.05. 
 
HF, high fat. 
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Figure 8.  Proposed mechanisms by which ECM-integrin-ILK signaling regulates muscle 
insulin resistance in HF-fed mice.  It is proposed that ILK will inhibit phosphorylation of Akt 
in the presence of insulin stimulation.  ILK also stimulates the phosphorylation and activation of 
JNK, P38, and ERK1/2 mitogen-activated protein kinases, which in turn inhibits capillary 
proliferation and therefore endothelial function in the muscle.  Both decreased phosphorylation 
of Akt and inhibited capillary proliferation contribute to muscle insulin resistance during the HF 
feeding.  HF, high fat. MAPKs, mitogen-activated protein kinases.  (-) Represents diminished 
effects. (+) Represents potentiated effects. 
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Figure S1 Increased clamp Rd in HF-fed ILKlox/loxHSAcre mice was due to both 
increased glycolytic and storage rates. Glycolysis was calculated by the rate of 3H- 
H2O accumulation in plasma during the ICv clamp and glucose storage rate (mainly 
glycogen) was calculated by subtracting the glycolytic rate from total clamp Ra/Rd 
(n=5-9). All data are represented as mean ± SEM. *p<0.05. HF, high fat. 
 m
 R
 N
 A
 
( n
 o
 r
 m
 a
 l 
iz
 e
 d
  
t o
  
C
 h
 o
 w
  
I L
 K
 l 
o
 x
 /
 l 
o
 x
 ) 
m
 R
 N
 A
 
( 
n
 o
 r
 m
 a
 l
 i 
z
 e
 d
  
t o
  
C
 h
 o
 w
  
I L
 K
 l
 o
 x
 /
 l 
o
 x
 )
 
m
 R
 N
 A
 
( 
n
 o
 r
 m
 a
 l
 i 
z
 e
 d
  
t o
  
C
 h
 o
 w
  
I L
 K
 l
 o
 x
 /
 l 
o
 x
 )
 
m
 R
 N
 A
 
( 
n
 o
 r
 m
 a
 l
 i 
z
 e
 d
  
t o
  
C
 h
 o
 w
  
I L
 K
 l
 o
 x
 /
 l 
o
 x
 )
 
4 
A B 
 
 
1 5 * * 
 
 
1 0 
 
 
5 
4 
 
C h o w  I L K l o x / l o x 
# 
3 
C h o w  I L K 
l o x / l o x 
H S A c r e 
H F  I L K l o x / l o x 2
 
H F  I L K 
l o x / l o x 
H S A c r e 
1 
 
 
C h o w  I L K l o x / l o x 
 
C h o w  I L K 
l o x / l o x 
H S A c r e 
 
H F  I L K l o x / l o x 
 
H F  I L K 
l o x / l o x 
H S A c r e 
 
0 
F 4 /8 0 
0 
T N F  IL - 1 
 
M a c r o p h a g e 
 
C D 
8 
 
P r o - in fla m m a to r y 
* 
C h o w  I L K l o x / l o x 
6 
* C h o w  I L K 
l o x / l o x 
H S A c r e 
* 
H F  I L K l o x / l o x 
 
H F  I L K 
l o x / l o x 
H S A c r e 
 
2 
 
# 
0 
1 .5 
 
 
1 .0 
 
 
0 .5 
 
 
C h o w  I L K l o x / l o x 
 
C h o w  I L K 
l o x / l o x 
H S A c r e 
* 
H F  I L K l o x / l o x 
 
H F  I L K 
l o x / l o x 
H S A c r e 
# 
IL - 1 0 Ar g - 1 
 
A n ti- in fla m m a to r y 
0 .0  
IL - 6 
 
Figure S2 Muscle-specific deletion of ILK caused changes in the status of adipose 
inflammation. This was possibly due to increased IL-6 secreted from muscle of 
HF-fed ILKlox/loxHSAcre mice compared to HF-fed ILKlox/lox mice. Gene 
expression in gonadal adipose tissue (A-C) and gastrocnemius muscle (D) was 
determined by real-time PCR. RNA was isolated from 50 mg of tissues using the Tri- 
reagent. cDNA was synthesized using Superscript II (Invitrogen). Real-time PCR 
analysis was performed using Taqman gene expression assays. The final relative 
concentration was calculated by 2(50-Ct) and was normalized to GAPDH. (A) Gene 
expression of total macrophage marker F4/80 in adipose tissue (n=3-5). (B) Gene 
expression of the pro-inflammatory markers TNFα and IL-1β in adipose tissue (n=3- 
5). (C) Gene expression of the anti-inflammatory markers IL-10 and Arg-1 in adipose 
tissue (n=3-5). (D) Gene expression of IL-6 in muscle (n=4-6). All data are 
represented as mean ± SEM. #p<0.05 compared with chow-fed mice with the same 
genotype. *p<0.05 compared with ILKlox/lox with the same diet. HF, high fat. 
